ArticleJournal of Cancer2017
Clinical Features, Pathological Findings and Treatment of Recurrent Dermatofibrosarcoma Protuberans.
Article in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Hotspots and future trends of dermatofibrosarcoma protuberans.Frontiers in oncology · 2024Pooled it
- The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans.The Pan African medical journal · 2019Pooled it
- Dermatofibrosarcoma Protuberans (DFSP): Diagnostics and Molecular Pathology.Current treatment options in oncology · 2025Review
- A Case of Recurrent Dermatofibrosarcoma Protuberans With Fibrosarcomatous Transformation.Cureus · 2025Article
- Successful treatment of metastatic dermatofibrosarcoma protuberans of the breast to the lungs with imatinib mesylate: a case report.Ecancermedicalscience · 2025Article
- Basal Cell Carcinoma: Comprehensive Review with Emphasis on Scar Tissue Manifestation and Post-Vaccination Incidence.Biomedicines · 2024Review
- Surgical Management of Pediatric Dermatofibrosarcoma Protuberans: About Two Challenging Case Reports.Global pediatric health · 2024Article
- Interscapular-thoracic Amputation: A Giant Dermatofibrosarcoma Protuberans Tumor.Journal of clinical practice and research · 2023Article
- Advanced dermatofibrosarcoma protuberans: an updated analysis of cases from an Indian sarcoma clinic.Future science OA · 2021Article
- Risk factors related to postoperative recurrence of dermatofibrosarcoma protuberans: A retrospective study and literature review.World journal of clinical cases · 2021Article
- The Ki-67 proliferation index predicts recurrence-free survival in patients with dermatofibrosarcoma protuberans.Bosnian journal of basic medical sciences · 2021Article
- Clinicopathological features of fibrosarcomatous dermatofibrosarcoma protuberans and the construction of a back-propagation neural network recognition model.Orphanet journal of rare diseases · 2021Article
- Usefulness of Dermoscopy to Provide Accurate Assessment of Skin Cancers.Clinical, cosmetic and investigational dermatology · 2021Article
- Dermatofibrosarcoma Protuberans: Update on the Diagnosis and Treatment.Journal of clinical medicine · 2020Review
- A Rare Malignant Disease, Dermatofibrosarcoma Protuberans of the Breast: A Retrospective Analysis and Review of Literature.BioMed research international · 2020Review
- Dermoscopy of Dermatofibrosarcoma Protuberans: What Do We Know?Dermatology practical & conceptual · 2019Article
- Dermatofibrosarcoma Protuberans: Retrospective Single Center Analysis Over 16 Years.Open access Macedonian journal of medical sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatofibrosarcoma protuberans (DESP) is a relatively rare and low-grade tumor of the skin and soft tissue. We review the clinical features, pathological findings and management of recurrent DESP with the aim to improve our understanding of this rare tumor. Fifty-seven patients were diagnosed with recurrent DFSP. The mean age at the presentation of DFSP was 30.9 years. The mean age at diagnosis of DFSP was 40.2 years. Chest wall was the dominant location. The histopathological diagnosis was ordinary DFSP (O-DFSP) in 46 cases and fibrosarcomatous DFSP (FS-DFSP) in 11 cases. No differences were noted between FS-DFSP and conventional DFSP in age at presentation and diagnosis, tumor size, as well as CD34 and SMA expression (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.